ADAR1 Capital Management »

Glycomimetics shares owned by ADAR1 Capital Management

Quarter-by-quarter ownership of Glycomimetics (GLYC) shares owned by ADAR1 Capital Management from 13F filings

Historical chart of ADAR1 Capital Management investment in Glycomimetics

Tip: Access up to 7 years of quarterly data

All positions including Glycomimetics held by ADAR1 Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Glycomimetics by ADAR1 Capital Management

Quarter filed Position value Share count Share price at filing
2024-03-31 $417k 139k 3.00

More positions owned by ADAR1 Capital Management

Alnylam Pharmaceuticals (ALNY)
Ea Series Trust Alpha Arch 1-3 (BOXX)
Roivant Sciences SHS (ROIV)
Spdr S&p 500 Etf Tr Tr Unit Put Option (SPY)
Protagonist Therapeutics (PTGX)
Cytokinetics Com New (CYTK)
Keros Therapeutics (KROS)
Royalty Pharma Shs Class A (RPRX)
Bridgebio Pharma (BBIO)
Merrimack Pharmaceuticals In Com New
Ascendis Pharma A/s Sponsored Adr (ASND)
Arbutus Biopharma (ABUS)
Avrobio Ord (AVRO)
Beigene Sponsored Adr (BGNE)
Invesco Qqq Tr Unit Ser 1 Put Option (QQQ)

View all positions for ADAR1 Capital Management

Top funds holding Glycomimetics

BVF
Vanguard Group
Siren
Goldman Sachs Group
Renaissance Technologies
BlackRock
BlackRock
Balyasny Asset Management
Geode Capital Management
Acadian Asset Management
State Street Corporation
Northern Trust
Two Sigma Advisers
HCR Wealth Advisors
GSA Capital Partners

View all funds holding Glycomimetics